Overview
InspireMD Q2 revenue rises 2.3%, beating analyst expectations, per LSEG data
Net income for Q2 missed analyst expectations, per LSEG data
Co received FDA approval and launched CGuard Prime in U.S. market
Outlook
Company plans to launch CGuard Prime in Europe in Q3
InspireMD focuses on scaling operations post-U.S. launch
Company aims to establish CGuard as standard for carotid disease
Result Drivers
FDA APPROVAL - Received FDA approval for CGuard Prime carotid stent system, driving U.S. market launch
EXCHANGE RATES - Revenue positively impacted by exchange rates, offsetting decreased revenue from Russia
OPERATING EXPENSES - Increased due to U.S. sales force expansion and CGuard Prime launch preparation
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | $1.78 mln | $1.52 mln (2 Analysts) |
Q2 Net Income | Miss | -$13.15 mln | -$12.90 mln (2 Analysts) |
Q2 Income From Operations | Beat | -$13.02 mln | -$13.10 mln (2 Analysts) |
Q2 Basic EPS | -$0.26 | ||
Q2 Gross Profit | $313,000 | ||
Q2 Operating Expenses | $13.33 mln |
Press Release: ID:nGNX4ZbSXW
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。